Health Economics and Outcomes Research (HEOR)
Statistical Analysis and Health Economic Modeling for Evidence-Driven Evaluation
Petauri delivers methodologically rigorous health economic modeling and advanced statistical analysis to support evidence-based decision making across the product lifecycle.
From early economic assessments to health technology assessment (HTA) submissions and post-launch evaluation, we support the development of decision-ready evidence designed to align with HTA methodologies and payer expectations across the UK, Europe, and the rest of the world.
Health Economic Modeling & Statistical Expertise
We support pharmaceutical, biotech, and medtech organizations with high-quality, fit-for-purpose HEOR analyses to inform reimbursement, access, and HTA decisions.
Our health economists are able to proactively identify and overcome complex modeling challenges to deliver credible, decision-ready economic evidence.
Our core modeling capabilities include:
- Cost-effectiveness models (global, local, and HTA specific)
- Budget impact models (global, local, and HTA specific)
- Early economic models
- Pricing and access models
- Value-based pricing models
- Market uptake models
- Service delivery models
- Field-based value tools and cost calculators (including interactive application-based digital tools)
- Model review, validation, and critique
- Health economics strategy development and critique
- Training, workshop, and short-course delivery on key modeling concepts
Our dedicated in-house Statistics Team apply a range of advanced statistical methods to address complex analytical challenges using clinical trial and real-world data.
Expertise and methodologies include:
- Meta-analysis and meta-regression
- Feasibility analysis and indirect treatment comparisons
- Real-world data analysis
- Survival analysis
- Treatment switching and crossover analysis
- Regression discontinuity designs
- Quality of life analyses
- Simulation studies
HEOR Evaluation for Reimbursement, Access, and HTA Across Markets
Our combined health economics and statistical expertise supports HEOR analyses across a range of reimbursement, access, and HTA environments, helping organizations navigate complexity, uncertainty, and evolving evidence requirements.
In practice, our HEOR work supports:
- Reimbursement and HTA submissions, with evaluation strategies and analyses designed to meet methodological expectations, anticipate potential areas of payer and HTA scrutiny, and support structured consideration and response to key objections where they arise
- Evidence generation and interpretation under uncertainty. Supporting transparent assessment of value, outcomes, and understanding and articulating the trade‑offs arising from costs, evidence limitations, pricing assumptions, and decision uncertainty
- Market access planning across geographies through adaptation of economic models and analyses to local comparators, data availability, and decision criteria, while carefully navigating cross-market consistency and the broader global value narrative
- Ongoing evaluation beyond submission, supporting post-launch evidence needs and refinement of access strategies
Our approach combines methodological rigor with practical application, supporting the development of HEOR evidence that is relevant, transparent, and useful across markets and different decision contexts.
Partner With Petauri
If you’re looking for support with HEOR, get in touch today.